Vasoactive intestinal peptide antagonist treatment during mouse embryogenesis impairs social behavior and cognitive function of adult male offspring

Experimental Neurology

Volumn 206, Issue 1, 2007, Pages 101-113

  Hill, Joanna M ^a   Cuasay, Katrina ^a   Abebe, Daniel T ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Autism; Cued and contextual fear conditioning; Neurodevelopmental disorder; Neuropeptide; Sex differences; Sociability; Social approach

Indexed keywords

VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTISM; COGNITION; COGNITIVE DEFECT; CONDITIONING; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; FEAR; FEMALE; HEALTH STATUS; MALE; MOTOR PERFORMANCE; NEWBORN; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; PROGENY; PROTEIN ANALYSIS; PROTEIN FUNCTION; RAT; SENSORY SYSTEM; SOCIAL BEHAVIOR; SOCIOPATHY; TASK PERFORMANCE;

AGING; ANIMALS; ANIMALS, NEWBORN; AUTISTIC DISORDER; AVOIDANCE LEARNING; BRAIN; COGNITION; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; FEMALE; HABITUATION, PSYCHOPHYSIOLOGIC; MALE; MENTAL DISORDERS; MICE; PEPTIDES; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; SEX CHARACTERISTICS; SMELL; SOCIAL BEHAVIOR; VASOACTIVE INTESTINAL PEPTIDE;

EID: 34250667575     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2007.04.004     Document Type: Article

References (102)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (1994), American Psychiatric Association, Washington, DC.
2. Arndt T.L., Stodgell C.J., and Rodier P.M. The teratology of autism. Int. J. Dev. Neurosci. 23 (2005) 189-199
3. Ashwood P., Murch S.H., Anthony A., Pellicer A.A., Torrente F., Thomson M.A., Walker-Smith J.A., and Wakefield A.J. Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopathology. J. Clin. Immunol. 23 (2003) 504-517
4. Bailey A., Luthert P., Dean A., Harding B., Janota I., Montgomery M., Rutter M., and Lantos P. A clinicopathological study of autism. Brain 121 (1998) 889-905
5. Baker J., Liu J.-P., Robertson E.J., and Efstratiadis A. Role of insulin like growth factors in embryonic and postnatal growth. Cell 75 (1993) 73-82
6. Bassan M., Zamostiano R., Davidson A., Pinhasov A., Giladi E., Perl O., Bassan H., Blat C., Gibney G., Glazner G., Brenneman D.E., and Gozes I. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J. Neurochem. 72 (1999) 1283-1293
7. Bellinger D.L., Lorton D., Brouzhon S., Felten S., and Felten D.L. The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation. Adv. Neuroimmol. 6 (1996) 5-27
8. Bielsky I.F., Hu S.B., Szegda K.L., Westphal H., and Young L.J. Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology 29 (2004) 483-493
9. Brenneman D.E., and Gozes I. A femtomolar-acting neuroprotective peptide. J. Clin. Invest. 97 (1996) 2299-2307
10. Brenneman D.E., Westbrook G.L., Fitzgerald S.P., Ennist D.L., Elkins K.L., Ruff M.R., and Pert C.B. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature 335 (1988) 639-642
11. Brenneman D.E., Nicol T., Warren D., and Bowers L.M. Vasoactive intestinal peptide: a neurotrophic releasing agent and an astroglial mitogen. J. Neurosci. Res. 25 (1990) 386-394
12. Brenneman D.E., Hill J.M., Glazner G.W., Gozes I., and Phillips T.W. Interleukin-1 alpha and vasoactive intestinal peptide: enigmatic regulation of neuronal survival J. Dev. Neurosci. 13 (1995) 187-200
13. Brenneman D.E., Hauser J., Spong C.Y., and Phillips T.W. VIP and d-ala-peptide T-amide release chemokines which prevent HIV-1 GP120-induced neuronal death. Brain Res. 838 (1999) 27-36
14. Christianson A.L., Chesler N., and Kromberg J.G.R. Fetal valproate syndrome-clinical and neurodevelopmental features in two sibling pairs. Dev. Med. Child Neurol. 36 (1994) 357-369
15. Colwell C.S., Michel S., Itri J., Rodriguez W., Tam J., Lelieve V., Hu Z., Liu X., and Waschek J.A. Disrupted circadian rhythms in VIP- and PHI-deficient mice. Am. J. Physiol., Regul. Integr. Comp. Physiol. 258 (2003) R939-R949
16. Crawley J.N. Designing mouse behavioral tasks relevant to autistic-like behaviors. Ment. Retard. Dev. Disabil. Res. Rev. 10 (2004) 248-258
17. Crawley J.N., and Paylor R. A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm. Behav. 31 (1997) 197-211
18. Crawley J.N., Belknap J.K., Collins A., Crabbe J.C., Franke W., Henderson H., Hitzemann R.J., Maxson S.C., Miner L.L., Silva A.J., Wehner J.M., Wynshaw-Boris A., and Paylor R. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology 132 (1997) 107-124
19. Crawley J.M., Chen T., Puri A., Sullivan T.L., Hill J.M., Young N.B., Nadler J.J., Moy S.S., Young L.J., Caldwell H.K., and Young W.S. Social approach behaviors in oxytocin knockout mice: comparison of two independent lines tested in different laboratory environments. Neuropeptides 41 (2007) 145-163
20. Croonenberghs J., Bosmans E., Deboutte D., Kenhis G., and Maes M. Activation of the inflammatory response system in autism. Neuropsychobiology 45 (2002) 1-6
21. Cross J.C. Genes regulating embryonic and fetal survival. Theriogenology 55 (2001) 193-207
22. Delgado M., Pozo D., and Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol. Rev. 56 (2004) 249-290
23. El-Gehani F., Tena-Sempere M., and Huhtaniemi I. Vasoactive intestinal peptide is an important endocrine regulatory factor of fetal rat testicular steroidogenesis. Endocrinology 139 (1998) 1474-1480
24. El-Gehani F., Tena-Sempere M., and Huhtaniemi I. Vasoactive intestinal peptide stimulates testosterone production by cultured fetal rat testicular cells. Mol. Cell. Endocrinol. 140 (1998) 175-178
25. Elia M., Ferri R., Musumeci S., DelGracco S., Bottitta M., Scuderi C., Miano G., Panerai S., Bertrand T., and Grubar J.C. Sleep in subjects with autistic disorder: a neurophysiological and psychological study. Brain Develop. 22 (2000) 88-92
26. Ferguson J.N., Young L.J., Hearn E.F., Matzuk M.M., Insel T.R., and Winslow J.T. Social amnesia in mice lacking the oxytocin gene. Nat. Genet. 25 (2000) 284-288
27. Fombonne E. Inflammatory bowel disease and autism. Lancet 351 (1998) 955
28. Furlano R.I., Anthony A., Day R., Brown A., McGarvey L., Thomson M.A., Davies S.E., Berelowitz M., Forbes A., Wakefield A.J., Walker-Smith J.A., and Murch S.H. Colonic CD8 and gamma delta T-cell infiltration with epithelial damage in children with autism. J. Pediatr. 138 (2001) 366-372
29. Furman S., Steingart R.A., Mandel S., Hauser J.M., Brenneman D.E., and Gozes I. Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biol. 1 (2004) 193-199
30. Gaffney G.R., Tsai L.Y., Kuperman S., and Minchin S. Cerebellar structure in autism. Am. J. Dis. Child. 141 (1987) 1330-1332
31. Glazner G.W., Gressens P., Lee S.J., Gibney G., Gozes I., Gozes Y., Brenneman D.E., and Hill J.M. Activity-dependent neurotrophic factor: a potent regulator of embryonic growth. Anat. Embryol. 200 (1999) 65-71
32. Glowa J.R., Panlilio L.V., Brenneman D.E., Gozes I., Fridkin M., and Hill J.M. Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist. Brain Res. 570 (1992) 49-53
33. Gozes I., Metzler E., Rubinrout S., Brenneman D.E., and Fridkin M. Vasoactive intestinal peptide potentiates sexual behavior: inhibition by novel antagonist. Endocrinology 125 (1989) 2945-2949
34. Gozes I., McCune S.K., Jacobson L., Warren D., Moody T.W., Fridkin M., and Brenneman D.E. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system. J. Pharmacol. Exp. Ther. 257 (1991) 959-966
35. Gressens P., Hill J.M., Gozes I., Fridkin M., and Brenneman D.E. Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature 362 (1993) 155-158
36. Gressens P., Hill J.M., Paindaveine P., Gozes I., Fridkin M., and Brenneman D.E. Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. J. Clin. Invest. 94 (1994) 2020-2027
37. Gressens P., Paindaveine B., Hill J.M., Evrard P., and Brenneman D.E. Vasoactive intestinal peptide shortens both G1 and S phases of cell cycle in whole cultured mouse embryos. Eur. J. Neurosci. 10 (1998) 1734-1742
38. Hill J.M. Vasoactive intestinal peptide in neurodevelopmental disorders: therapeutic potential. Curr. Pharm. Des. 13 (2007) 1079-1089
39. Hill J.M., Gozes I., Hill J.L., Fridkin M., and Brenneman D.E. Vasoactive intestinal peptide antagonist retards the development of neonatal behaviors in the rat. Peptides 12 (1991) 187-192
40. Hill J.M., Mervis R.F., Politi J., McCune S.K., Gozes I., Fridkin M., and Brenneman D.E. Blockade of VIP during neonatal development induces neuronal damage and increases VIP and VIP receptors in brain. Ann. N. Y. Acad. Sci. 739 (1994) 211-225
41. Hill J.M., McCune S.K., Alvero R.J., Glazner G.W., Henins K.A., Stanziale S.F., Keimowitz J.R., and Brenneman D.E. Maternal vasoactive intestinal peptide and the regulation of embryonic growth in the rodent. J. Clin. Invest. 97 (1996) 202-208
42. Hill J.M., Lee S.J., Dibbern D.A., Fridkin M., Gozes I., and Brenneman D.E. Pharmacologically distinct vasoactive intestinal peptide binding sites: CNS localization and role in embryonic growth. Neurosci. 93 (1999) 783-791
43. Hill J.M., Mehnert J., McCune S.K., and Brenneman D.E. Vasoactive intestinal peptide regulation of nerve growth factor in the embryonic mouse. Peptides 23 (2002) 1803-1808
44. Hill J.M., Ades A.M., McCune S.K., Sahir N., Moody E.M., Abebe D.T., Crnic L.S., and Brenneman D.E. Vasoactive intestinal peptide in the brain of a mouse model for Down syndrome. Exp. Neurol. 183 (2003) 56-65
45. Hill, J.M., Hauser, J.M., Sheppard, L.M., Abebe, D., Spivak-Pohis, U., Kushnir, M., Deitch, I., Gozes, I., (in press). Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry. J. Mol. Neurosci.
46. Holmes A., Hollon T.R., Gleason T.C., Liu Z., Dreiling J., Sibley D.R., and Crawley J.N. Behavioral characterization of dopamine D-5 receptor null mutant mice. Behav. Neurosci. 115 (2001) 1129-1144
47. Holmes A., Wrenn C.C., Harris A.P., Thayer K., and Crawley J.N. Behavioral profiles of inbred strains on novel, olfactory, spatial and emotional tests for reference memory in mice. Genes Brain Behav. 1 (2002) 55-69
48. Holmes A., Kinney J.W., Wrenn C.C., Li Q., Yang R.J., Ma L., Vishwanath J., Saavedra M.C., Innerfield C.E., Jacoby A.S., Shine J., Lismaa T.P., and Crawley J.N. Galanin GAL-R1 receptor null mutant mice display increased anxiety-like behavior specific to the elevated plus maze. Neuropsychopharmacology 28 (2003) 1031-1044
49. Ingram J.L., Peckham M., Tisdale B., and Rodier P.M. Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicol. Teratol. 22 (2000) 319-324
50. Insel T.F., and Young L.J. Neuropeptides and the evolution of social behavior. Curr. Opin. Neurbiol. 1 (2000) 784-789
51. Ishihara T., Shigemoto R., Mori K., Takahashi K., and Nagata S. Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8 (1992) 811-819
52. Iwasaki Y., Ikeda K., Ichikawa Y., and Igarashi O. Vasoactive intestinal peptide influences neurite outgrowth in cultured rat spinal cord neurons. Neurol. Res. 23 (2001) 851-854
53. Jessell T.M., and Dodd J. Floor plate-derived signals and the control of neural cell pattern in vertebrates. Harvey Lect. Ser. 86 (1992) 87-128
54. Kanner L. Autistic disturbances of affective contact. Nerv. Child 2 (1943) 217-250
55. King D.L., and Arendash G.W. Maintained synaptophysin immunoreactivity in Tg2576 transgenic mice during aging: correlations with cognitive impairment. Brain Res. 926 (2002) 58-68
56. Klar A., Baldassare M., and Jessell T.M. F-spondin-a gene expressed at high levels in the floor plate encodes a secreted protein that promotes neural cell adhesion and neurite extension. Cell 69 (1992) 95-110
57. Limoges E., Mottron L., Boldus C., Berthiaume C., and Godbout R. Atypical sleep architecture and the autism phenotype. Brain 128 (2005) 1049-1061
58. Liu J.-P., Baker J., Perkins A.S., Robertson E.J., and Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor-1 (IGF-1) and type-1 IGF receptor (IGF-1R). Cell 75 (1993) 59-72
59. Lord C., Risi S., Lambrecht L., Cook Jr. E.H., Leventhal B.L., DiLavore P.C., Pickles A., and Rutter M. The Autism Diagnostic Observtion Schedule-Generic: a standard measure of social and communication deficits associated with the spectrum of autism. J. Autism Dev. Disord. 30 (2000) 205-223
60. Lu N.R., Black I.B., and DiCicco-Bloom E. A paradigm for distinguishing the roles of mitogenesis and trophism in neuronal precursor proliferation. Dev. Brain Res. 94 (1996) 31-36
61. Lutz E.M., Sheward WJ., West K.M., Morrow J.A., and Harmar A.J. The VIP2 receptor: molecular characterization of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett. 334 (1993) 3-8
62. Meresse I.G., Zilbovicius M., Boddaert N., Robel L., Philippe A., Sfaello I., Laurier L., Brunelle F., Samson Y., Mouren M.C., and Chabane N. Autism severity and temporal lobe functional abnormalities. Ann. Neurol. 58 (2005) 466-469
63. McEchron M.D., Bouwmeester J., Tseng W., Weiss C., and Disterhoft J.F. Hippocampectomy disrupts auditory trace fear conditioning and contextual fear conditioning in the rat. Hippocampus 8 (1998) 638-646
64. McEchron M.D., Tseng W., and Disterhoft J.F. Single neurons in CA1 hippocampus encode trace interval duration during trace heart rate (fear) conditioning in rabbit. J. Neurosci. 23 (2003) 1535-1547
65. Miller M.T., and Stromland K. Thalidomide embryopathy: an insight into autism?. Teratology 47 (1993) 387-388
66. Miyazaki K., Narita N., and Narita M. Maternal administration of thalidomide or valproic acid causes abnormal serotonergic neurons in the offspring: implication for pathogenesis of autism. Int. J. Dev. Neurosci. 23 (2005) 287-2997
67. Moody T.W., Zia F., Draoui M., Brenneman D.E., Fridkin M., Davidson A., and Gozes I. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 4345-4349
68. Moody T.W., Jensen R.T., Fridkin M., and Gozes I. (N-stearyl, Norleucine17) VIP hybrid is a broad vasoactive intestinal peptide receptor antagonist. J. Mol. Neurosci. 18 (2002) 29-35
69. Moy S.S., Nadler J.J., Perez A., Barbaro R.P., Johns J.M., Magnuson T.R., Piven J., and Crawley J.N. Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Genes Brain Behav. 3 (2004) 287-302
70. Nadler J.J., Moy S.S., Dold G., Trang D., Simmons N., Perez A., Young N.B., Barbaro R.P., Piven J., Magnuson T.R., and Crawley J.N. Automated apparatus for quantitation of social approach behaviors in mice. Genes Brain Behav. 3 (2004) 303-314
71. Nanson J.L. Autism in fetal alcohol syndrome-a report of six cases. Alcohol Clin. Exp. Res. 16 (1992) 558-565
72. Nelson K.B., Grether J.K., Croen L.A., Dambrosia J.M., Dickens B.F., Hansen R.L., and Phillips R.M. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann. Neurol. 49 (2001) 597-606
73. Nicot A., Otto T., Brabet P., and DiCicco-Bloom E.M. Altered social behavior in pituitary adenylate cyclase-activating polypeptide type 1 receptor-deficient mice. J. Neurosci. 24 (2004) 8786-8795
74. Okumura N., Miyatake Y., Takao T., Tamaru T., Nagai K., and Nakagawa H. Vasoactive intestinal peptide induces differentiation and MAP kinase activation in PC12 cells. J. Biochem. (Tokyo) 115 (1994) 304-308
75. Paylor R., Nguyen M., Crawley J.N., Patrick J., Beaudet A., and Orr-Urtreger A. Alpha 7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating: a behavioral characterization of Acra7-deficient mice. Learn. Memory 5 (1998) 301-316
76. Pincus D.W., DiCicco-Bloom E.M., and Black I.B. Vasoactive intestinal peptide regulation of neuroblast mitosis and survival: role of cAMP. Brain Res. 514 (1990) 355-357
77. Pincus D.W., DiCicco-Bloom E.M., and Black I.B. Trophic mechanisms regulate mitotic neuronal precursors: role of vasoactive intestinal peptide (VIP). Brain Res. 663 (1994) 51-60
78. Pinhasov A., Mandel S., Torchinsky A., Giladi E., Pittel Z., Goldsweig A.M., Servoss S.J., Brenneman D.E., and Gozes I. Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Dev. Brain Res. 144 (2003) 83-90
79. Pisegna J., and Wank S.A. Molecular cloning and functional expression of the pituitary adenylate cyclase activation polypeptide type 1 receptor. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 6345-6349
80. Powell-Braxton L., Hollingshead P., Warburton C., Dowd M., Pitts-Mee S., Dalton D., Gillett N., and Stewart T.A. IGF-1 is required for normal embryonic growth in mice. Genes Dev. 7 (1993) 2609-2617
81. Rodier P.M., Ingram J.L., Tisdale B., Nelson S., and Romano J. Embryological origin for autism: developmental anomalies of the cranial nerve motor nuclei. J. Comp. Neurol. 370 (1996) 247-261
82. Rodier P.M., Ingram J.L., Tisdale B., and Croog V.J. Linking etiologies in humans and animal models: studies of autism. Reprod. Toxicol. 11 (1997) 417-422
83. Romanelli F., Fillo S., Isidori A., and Conte D. Pituitary adenylate cyclase-activating polypeptide regulates rat Leydig cell function in vitro. Neuropeptides 31 (1997) 311-317
84. Sahir N., Brenneman D.E., and Hill J.M. Neonatal mice of the Down syndrome model, Ts65Dn, exhibit upregulated VIP measures and reduced responsiveness of cortical astrocytes to VIP stimulation. J. Mol. Neurosci. 30 (2006) 81-92
85. Santangelo S.L., and Tsatsanis K. What is known about autism-genes, brain, and behavior. Am. J. Pharmacogenomics 5 (2005) 71-92
86. Schneider T., and Przewlocki R. Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 30 (2005) 80-89
87. Servoss S.J., Lee S.J., Gibney G., Brenneman D.E., and Hill J.M. Insulin-like growth factor-I as a mediator of vasoactive intestinal peptide/activity-dependent neurotrophic factor-stimulated embryonic growth. Endocrinology 142 (2001) 3348-3353
88. Sigalov E., Fridkin M., Brenneman D.E., and Gozes I. VIP-related protection against iodoacetate toxicity in pheochromocytoma (PC12) cells. J. Mol. Neurosci. 15 (2000) 147-154
89. Simon-Arceo K., Ramirex-Salado I., and Calvo J.M. Long-lasting enhancement of rapid eye movement sleep and pontogeniculooccipital waves by vasoactive intestinal peptide microinjection into the amygdala temporal lobe. Sleep 26 (2003) 259-264
90. Spong C.V., Lee S.J., McCune S.K., Gibney G., Abebe T.D., Alvero R., Brenneman D.E., and Hill J.M. Maternal regulation of embryonic growth: the role of vasoactive intestinal peptide. Endocrinology 140 (1999) 917-924
91. Spong C.Y., Auth J., Vink J., Goodwin K., Abebe D.T., Hill J.M., and Brenneman D.E. Vasoactive intestinal peptide mRNA and immunoreactivity are decreased in fetal alcohol syndrome model. Regul. Pept. 108 (2002) 143-147
92. Stromland K., Nordin V., Miller M.T., Akerstrom B., and Gillberg C. Autism in thalidomide embryopathy-a population study. Dev. Med. Child Neurol. 36 (1994) 351-356
93. Taira M., Takase M., and Sasaki H. Sleep disorder in children with autism. Psychiatry Clin. Neurosci. 52 (1998) 182-183
94. Thirumalai S.S., Shubin R.A., and Robinson R. Rapid eye movement sleep behavior disorder in children with autism. J. Child Neurol. 17 (2002) 173-178
95. Usdin T.B., Bonner T.I., and Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135 (1994) 2662-2680
96. Villalpando I., and Lopez-Olmos V. Insulin-like growth factor 1 (IGF-1) regulates endocrine activity of the embryonic testis in the mouse. J. Steroid Biochem. Mol. Biol. 86 (2003) 151-158
97. Waschek J.A., Elloison J., Bravo D.T., and Handley V. Embryonic expression of vasoactive intestinal peptide (VIP) and VIP receptor genes. Neurochemistry 66 (1996) 1762-1765
98. Williams P.G., and Hersch J.H. A male with fetal valproate syndrome and autism. Dev. Med. Child Neurol. 36 (1997) 632-634
99. Williams G., King J., Cunningham M., Steohan M., Kerr B., and Hersh J.H. Fetal valproate syndrome and autism: additional evidence of an association. Dev. Med. Child Neurol. 43 (2001) 202-206
100. Williams P.G., Sears L.L., and Allard A. Sleep problems in children with autism. J. Sleep Res. 13 (2004) 265-268
101. Wrenn C.C., Kinney J.W., Mrriott L.K., Holmes A., Harris A.P., Saavedra M.C., Starosta G., Innerfield C.E., Jacoby A.S., Shine J., Lismaa T.P., Wenk G.L., and Crawley J.N. Learning and memory performance in mice lacking the GAL-R1 subtype of galanin receptor. Eur. J. Neurosci. 19 (2004) 1384-1396
102. Wu J., Henins K.A., Gressens P., Gozes I., Fridkin M., Brenneman D.E., and Hill J.M. Prenatal blockage of vasoactive intestinal peptide delays developmental milestones in the neonatal mouse. Peptides 18 (1997) 1131-1137